The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.
- DOI
- 10.1002/hem3.138
- Published
- 2024 Aug
- Container
- HemaSphere
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/hem3.138,
title = {The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.},
author = {Zelenetz AD and Jurczak W and Ribrag V and Linton K and Collins GP and Jiménez JL and Bishton M and Dholaria B and Mengarelli A and Phillips TJ and Sungala N and Musuraca G and Sheehy O and Van Den Neste E and Odera M and Miao L and Gold DP and Ghalie RG and Zinzani PL},
year = {2024},
journal = {HemaSphere},
doi = {10.1002/hem3.138},
url = {https://doi.org/10.1002/hem3.138}
}RIS
TY - JOUR TI - The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study. AU - Zelenetz AD AU - Jurczak W AU - Ribrag V AU - Linton K AU - Collins GP AU - Jiménez JL AU - Bishton M AU - Dholaria B AU - Mengarelli A AU - Phillips TJ AU - Sungala N AU - Musuraca G AU - Sheehy O AU - Van Den Neste E AU - Odera M AU - Miao L AU - Gold DP AU - Ghalie RG AU - Zinzani PL PY - 2024 JO - HemaSphere DO - 10.1002/hem3.138 UR - https://doi.org/10.1002/hem3.138 ER -
APA
AD, Z., W, J., V, R., K, L., GP, C., JL, J., M, B., B, D., A, M., TJ, P., N, S., G, M., O, S., E, V. D. N., M, O., L, M., DP, G., RG, G., & PL, Z. (2024). The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.. HemaSphere. https://doi.org/10.1002/hem3.138
Source records
- pubmed · retrieved 2026-09-26T09:33:07.943Z